Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 1
2009 4
2010 2
2011 7
2012 6
2013 16
2014 18
2015 27
2016 20
2017 7
2018 9
2019 1
2020 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 25983157

111 results

Results by year

Filters applied: . Clear all
Page 1
Pathological aspects of bioresorbable stent implantation.
Sanchez OD, Yahagi K, Byrne RA, Mori H, Zarpak R, Wittchow E, Foin N, Virmani R, Joner M. Sanchez OD, et al. EuroIntervention. 2015;11 Suppl V:V159-65. doi: 10.4244/EIJV11SVA39. EuroIntervention. 2015. PMID: 25983157 Free article. Review.
First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J, Webster M, Stewart J, Vrolix M, Whitbourn R, Donohoe D, Knape C, Lansky A, Attizzani GF, Fitzgerald P, Kandzari DE, Wijns W. Ormiston J, et al. JACC Cardiovasc Interv. 2013 Oct;6(10):1026-34. doi: 10.1016/j.jcin.2013.05.013. Epub 2013 Sep 18. JACC Cardiovasc Interv. 2013. PMID: 24055443 Free article. Clinical Trial.
Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Onuma Y, Serruys PW, Muramatsu T, Nakatani S, van Geuns RJ, de Bruyne B, Dudek D, Christiansen E, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Garcia-Garcia HM, Veldhof S, Rapoza R, Ormiston JA. Onuma Y, et al. JACC Cardiovasc Interv. 2014 Dec;7(12):1400-11. doi: 10.1016/j.jcin.2014.06.016. JACC Cardiovasc Interv. 2014. PMID: 25523532 Free article. Clinical Trial.
Difference in neointimal appearance between early and late restenosis after sirolimus-eluting stent implantation assessed by optical coherence tomography.
Ino Y, Kubo T, Kitabata H, Ishibashi K, Tanimoto T, Matsuo Y, Shimamura K, Shiono Y, Orii M, Komukai K, Yamano T, Yamaguchi T, Hirata K, Tanaka A, Mizukoshi M, Imanishi T, Akasaka T. Ino Y, et al. Coron Artery Dis. 2013 Mar;24(2):95-101. doi: 10.1097/MCA.0b013e32835c872b. Coron Artery Dis. 2013. PMID: 23363984
Drug-eluting stent implantation in patients with acute coronary syndrome - the Activity of Platelets after Inhibition and Cardiovascular Events: Optical Coherence Tomography (APICE OCT) study.
Chieffo A, Buchanan GL, Parodi G, Versaci F, Bianchi RM, Valenti R, Saccà S, Mongiardo A, Span S, Migliorini A, Spaccarotella C, Reimers B, Antoniucci D, Indolfi C, Ferrari A, Maehara A, Mintz GS, Colombo A. Chieffo A, et al. EuroIntervention. 2014 Dec;10(8):916-23. doi: 10.4244/EIJY14M06_10. EuroIntervention. 2014. PMID: 24974806 Free article. Clinical Trial.
111 results